Business Context and Reporting Period
Company: Prestige Brands Holdings, Inc. (filing as Prestige Consumer Healthcare Inc. in metadata)
Filing Type: Form 8-K (Current Report)
Date: April 25, 2014
Event: Entry into a Material Definitive Agreement to acquire Insight Pharmaceuticals Corporation.
Key Financial Metrics
This filing reports a specific transaction rather than periodic financial results. No revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period are provided in this text.
- Transaction Value: $750 million total purchase price.
- Escrow Amount: $32 million held for 15 months to cover indemnification claims.
- Adjustments: Purchase price subject to closing adjustments based on Insight's working capital.
Material Changes
The primary material change is the execution of a Stock Purchase Agreement to acquire 100% of the issued and outstanding capital stock of Insight Pharmaceuticals Corporation, a privately-held developer and distributor of over-the-counter health care products. The transaction is expected to close in the second quarter of the Company's fiscal year.
Guidance, Outlook, and Risks
Outlook: Management expects the transaction to close in the second quarter of the fiscal year.
Conditions to Closing: The deal is subject to customary conditions, including:
- Expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- Absence of laws or injunctions prohibiting the transaction.
- Accuracy of representations and warranties (subject to material adverse effect standards).
Termination Rights: The agreement may be terminated if closing does not occur by December 31, 2014, or if a party breaches the agreement and fails to cure the breach.
Investor Verification Checklist
- Verify the final purchase price after working capital adjustments at closing.
- Confirm the actual closing date relative to the expected second-quarter timeline.
- Monitor regulatory approval status under the Hart-Scott-Rodino Act.
- Review the full Stock Purchase Agreement (expected as an exhibit to the Form 10-K for the year ended March 31, 2014) for detailed indemnification limitations and covenants.
- Assess the impact of the $32 million escrow holdback on immediate cash flow upon closing.